|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-Small-Cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rodríguez-Abreu D, Powell SF, Hochmair MJ,
Gadgeel S, Esteban E, Felip E, Speranza G, De Angelis F, Dómine M,
Cheng SY, et al: Pemetrexed plus platinum with or without
pembrolizumab in patients with previously untreated metastatic
nonsquamous NSCLC: Protocol-specified final analysis from
KEYNOTE-189. Ann Oncol. 32:881–895. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Socinski MA, Nishio M, Jotte RM, Cappuzzo
F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D,
Moro-Sibilot D, Thomas CA, et al: IMpower150 Final overall survival
analyses for atezolizumab plus bevacizumab and chemotherapy in
first-line metastatic nonsquamous NSCLC. J Thorac Oncol.
16:1909–1924. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hellmann MD, Paz-Ares L, Bernabe Caro R,
Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A,
Lupinacci L, de la Mora Jimenez E, et al: Nivolumab plus Ipilimumab
in Advanced Non-Small-Cell lung cancer. N Engl J Med.
381:2020–2031. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Paz-Ares L, Ciuleanu TE, Cobo M, Schenker
M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E,
Juan-Vidal O, et al: First-line nivolumab plus ipilimumab combined
with two cycles of chemotherapy in patients with non-small-cell
lung cancer (CheckMate 9LA): An international, randomised,
open-label, phase 3 trial. Lancet Oncol. 22:198–211. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee
JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers
S, Salman P, et al: Nivolumab plus Ipilimumab in lung cancer with a
high tumor mutational burden. N Engl J Med. 378:2093–2104. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Marabelle A, Le DT, Ascierto PA, Di
Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M,
Penel N, Hansen AR, et al: Efficacy of pembrolizumab in patients
with noncolorectal high microsatellite instability/mismatch
Repair-Deficient cancer: Results from the phase II KEYNOTE-158
study. J Clin Oncol. 38:1–10. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nomizo T, Ozasa H, Tsuji T, Funazo T,
Yasuda Y, Yoshida H, Yagi Y, Sakamori Y, Nagai H, Hirai T and Kim
YH: Clinical impact of single nucleotide polymorphism in PD-L1 on
response to nivolumab for advanced non-small-cell lung cancer
patients. Sci Rep. 7:451242017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Funazo TY, Nomizo T, Ozasa H, Tsuji T,
Yasuda Y, Yoshida H, Sakamori Y, Nagai H, Hirai T and Kim YH:
Clinical impact of low serum free T4 in patients with non-small
cell lung cancer treated with nivolumab. Sci Rep. 9:170852019.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yoshida H, Nomizo T, Ozasa H, Tsuji T,
Funazo T, Yasuda Y, Ajimizu H, Yamazoe M, Kuninaga K, Ogimoto T, et
al: PD-L1 polymorphisms predict survival outcomes in advanced
non-small-cell lung cancer patients treated with PD-1 blockade. Eur
J Cancer. 144:317–325. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bonaventura P, Shekarian T, Alcazer V,
Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, Caux C and
Depil S: Cold Tumors: A therapeutic challenge for immunotherapy.
Front Immunol. 10:1682019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tong N, He Z, Ma Y, Wang Z, Huang Z, Cao
H, Xu L, Zou Y, Wang W, Yi C, et al: Tumor associated macrophages,
as the dominant immune cells, are an indispensable target for
immunologically cold Tumor-Glioma therapy? Front Cell Dev Biol.
9:7062862021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Strauss O, Dunbar PR, Bartlett A and
Phillips A: The immunophenotype of antigen presenting cells of the
mononuclear phagocyte system in normal human liver-a systematic
review. J Hepatol. 62:458–468. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mehta AK, Kadel S, Townsend MG, Oliwa M
and Guerriero JL: Macrophage biology and mechanisms of immune
suppression in breast cancer. Front Immunol. 12:6437712021.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miller YE, Daniels GL, Jones C and Palmer
DK: Identification of a cell-surface antigen produced by a gene on
human chromosome 3 (cen-q22) and not expressed by Rhnull cells. Am
J Hum Genet. 41:1061–1070. 1987.PubMed/NCBI
|
|
19
|
Oldenborg PA, Zheleznyak A, Fang YF,
Lagenaur CF, Gresham HD and Lindberg FP: Role of CD47 as a marker
of self on red blood cells. Science. 288:2051–2054. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Russ A, Hua AB, Montfort WR, Rahman B,
Riaz IB, Khalid MU, Carew JS, Nawrocki ST, Persky D and Anwer F:
Blocking ‘don't eat me’ signal of CD47-SIRPα in hematological
malignancies, an in-depth review. Blood Rev. 32:480–489. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jaiswal S, Jamieson CH, Pang WW, Park CY,
Chao MP, Majeti R, Traver D, van Rooijen N and Weissman IL: CD47 is
upregulated on circulating hematopoietic stem cells and leukemia
cells to avoid phagocytosis. Cell. 138:271–285. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hayat SMG, Bianconi V, Pirro M, Jaafari
MR, Hatamipour M and Sahebkar A: CD47: Role in the immune system
and application to cancer therapy. Cell Oncol (Dordr). 43:19–30.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Arrieta O, Aviles-Salas A, Orozco-Morales
M, Hernández-Pedro N, Cardona AF, Cabrera-Miranda L, Barrios-Bernal
P, Soca-Chafre G, Cruz-Rico G, Peña-Torres ML, et al: Association
between CD47 expression, clinical characteristics and prognosis in
patients with advanced non-small cell lung cancer. Cancer Med.
9:2390–2402. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Weiskopf K, Jahchan NS, Schnorr PJ,
Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim
JS, et al: CD47-blocking immunotherapies stimulate
macrophage-mediated destruction of small-cell lung cancer. J Clin
Invest. 126:2610–2620. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang X, Fan J, Wang S, Li Y, Wang Y, Li
S, Luan J, Wang Z, Song P, Chen Q, et al: Targeting CD47 and
autophagy elicited enhanced antitumor effects in Non-Small cell
lung cancer. Cancer Immunol Res. 5:363–375. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lascorz J, Bevier M, V Schönfels W,
Kalthoff H, Aselmann H, Beckmann J, Egberts J, Buch S, Becker T,
Schreiber S, et al: Association study identifying polymorphisms in
CD47 and other extracellular matrix pathway genes as putative
prognostic markers for colorectal cancer. Int J Colorectal Dis.
28:173–181. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Felip E, Ardizzoni A, Ciuleanu T, Cobo M,
Laktionov K, Szilasi M, Califano R, Carcereny E, Griffiths R,
Paz-Ares L, et al: CheckMate 171: A phase 2 trial of nivolumab in
patients with previously treated advanced squamous non-small cell
lung cancer, including ECOG PS 2 and elderly populations. Eur J
Cancer. 127:160–172. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kitadai R, Okuma Y, Hakozaki T and Hosomi
Y: The efficacy of immune checkpoint inhibitors in advanced
non-small-cell lung cancer with liver metastases. J Cancer Res Clin
Oncol. 146:777–785. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Deng N, Zhou H, Fan H and Yuan Y: Single
nucleotide polymorphisms and cancer susceptibility. Oncotarget.
8:110635–110649. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao H, Song S, Ma J, Yan Z, Xie H, Feng Y
and Che S: CD47 as a promising therapeutic target in oncology.
Front Immunol. 13:7574802022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Murata Y, Saito Y, Kotani T and Matozaki
T: CD47-signal regulatory protein α signaling system and its
application to cancer immunotherapy. Cancer Sci. 109:2349–2357.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
DeNardo DG and Ruffell B: Macrophages as
regulators of tumour immunity and immunotherapy. Nat Rev Immunol.
19:369–382. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fujiwara-Tani R, Sasaki T, Ohmori H, Luo
Y, Goto K, Nishiguchi Y, Mori S, Nakashima C, Mori T, Miyagawa Y,
et al: Concurrent Expression of CD47 and CD44 in colorectal cancer
promotes malignancy. Pathobiology. 86:182–189. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gordon SR, Maute RL, Dulken BW, Hutter G,
George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, et al:
PD-1 expression by tumour-associated macrophages inhibits
phagocytosis and tumour immunity. Nature. 545:495–499. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Advani R, Flinn I, Popplewell L, Forero A,
Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP,
et al: CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's
Lymphoma. N Engl J Med. 379:1711–1721. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sikic BI, Lakhani N, Patnaik A, Shah SA,
Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S,
Papadopoulos K, et al: First-in-human, first-in-class phase I trial
of the anti-CD47 antibody Hu5F9-G4 in patients with advanced
cancers. J Clin Oncol. 37:946–953. 2019. View Article : Google Scholar : PubMed/NCBI
|
